Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems

Cynthia L. Leibson, Kirsten Hall Long

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions. Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.

Original languageEnglish (US)
Pages (from-to)1239-1262
Number of pages24
JournalPharmacoEconomics
Volume21
Issue number17
DOIs
StatePublished - 2003

Fingerprint

Attention Deficit Disorder with Hyperactivity
Economics
Delivery of Health Care
Costs and Cost Analysis
Cost of Illness
Mental Health Services
Health Policy
Cost-Benefit Analysis
Psychiatry
Cross-Sectional Studies
Pharmacology
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems. / Leibson, Cynthia L.; Long, Kirsten Hall.

In: PharmacoEconomics, Vol. 21, No. 17, 2003, p. 1239-1262.

Research output: Contribution to journalArticle

Leibson, Cynthia L. ; Long, Kirsten Hall. / Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems. In: PharmacoEconomics. 2003 ; Vol. 21, No. 17. pp. 1239-1262.
@article{262dc6fc03984bd18e1924aeec1ada7e,
title = "Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems",
abstract = "Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions. Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.",
author = "Leibson, {Cynthia L.} and Long, {Kirsten Hall}",
year = "2003",
doi = "10.2165/00019053-200321170-00002",
language = "English (US)",
volume = "21",
pages = "1239--1262",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "17",

}

TY - JOUR

T1 - Economic Implications of Attention-Deficit Hyperactivity Disorder for Healthcare Systems

AU - Leibson, Cynthia L.

AU - Long, Kirsten Hall

PY - 2003

Y1 - 2003

N2 - Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions. Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.

AB - Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions. Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.

UR - http://www.scopus.com/inward/record.url?scp=0347589390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347589390&partnerID=8YFLogxK

U2 - 10.2165/00019053-200321170-00002

DO - 10.2165/00019053-200321170-00002

M3 - Article

VL - 21

SP - 1239

EP - 1262

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 17

ER -